Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02565186 · ClinicalTrials.gov registry record · Phase 3
An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,171
- Enrollment target
NCT02565186 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 2,171 participants.
The verdict
NCT02565186, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,171 participants
- Enrollment target
Study Summary
This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects with migraine. The study is designed to evaluate the safety and tolerability of long-term intermittent use of lasmiditan 100 mg and of lasmiditan 200 mg, as the first dose and as a second dose, for the acute treatment of migraine. Long term efficacy will also be evaluated.
Interventions
- DRUG Lasmiditan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,171 participants |
| Start Date | 2015-10-07 |
| Est. Completion | 2019-08-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02565186
The ClinicalTrials.gov registry entry for NCT02565186 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,171 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lasmiditan is the first listed.
NCT02565186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02565186 about?
NCT02565186 is a clinical study titled "An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine". This is a prospective, randomized, open-label study in subjects with migraine who have completed the Phase 3 studies, COL MIG 301/LAHJ (NCT02439320) or COL MIG-302/LAHK (NCT02605174) or for a subset of lasmiditan-naïve subjects with migraine. The study is designed to evaluate the safety and tolerabi...
What is the current status of trial NCT02565186?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,171 participants. The study started on 2015-10-07. Estimated completion is 2019-08-20.
What interventions are being tested in trial NCT02565186?
The interventions under investigation include: Lasmiditan (DRUG).
Who is sponsoring clinical trial NCT02565186?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.